| SAGIMET BIOSCIENCES |
| USA |
| Gesundheit |
| US7867001049 / A3CPAM |
| 0O2 (Frankfurt) / SGMT (NASDAQ) |
| FRA:0O2, ETR:0O2, 0O2:GR, NASDAQ:SGMT |
| - |
| https://www.sagimet.com/ |
|
Sagimet Biosciences Inc. is a biotechnology company focused on the development of therapeutics targeting critical metabolic pathways in fibrotic diseases and cancer. The company's primary function is to leverage its proprietary platform to discover a..
>Volltext.. |
| 145.34 Mio. EUR |
| 49.14 Mio. EUR |
| - |
| -49.28 Mio. EUR |
| -44.21 Mio. EUR |
| -1.37 EUR |
| 0.07 Mio. EUR |
| 30.34 Mio. EUR |
| -39.55 Mio. EUR |
| 22.18 |
| - |
| 1.28% |
| - |
| - |
| - |
| - |
| SAGIMET |
| 04.04.26 |
|